Claritin Reditabsloratadine

According to the FDA label: Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: • runny nose • itchy, watery eyes • sneezing • itching of the nose or throat

101,317 adverse event reports submitted to the FDA (2003–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with Claritin Reditabs in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
Claritin Reditabs adverse event reports by reporter sex
SexReports
Female61,261
Male31,011
Unknown279

By Age Group

View age group data as a table
Claritin Reditabs adverse event reports by reporter age group
Age groupReports
0-176,383
18-346,611
35-499,780
50-6417,045
65-7411,963
75+9,657

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included Claritin Reditabs. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
Claritin Reditabs adverse event reports by reported outcome
OutcomeReports
Non-Serious53,171
Other Serious31,559
Hospitalization22,451
Death4,433
Life-Threatening2,458
Disability2,153

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for Claritin Reditabs. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
Claritin Reditabs adverse event reports by year
YearReports
20031
2004966
20051,080
20061,075
2007947
20081,077
20091,328
20101,643
20112,035
20123,278
20134,246
20144,999
20157,321
20168,813
20178,781
20187,752
20197,831
20207,033
20216,294
20226,120
20235,515
20246,014
20255,900
2026 (partial)1,268

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with Claritin Reditabs

In FDA adverse event reports that mention Claritin Reditabs, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026